| scholarly article | Q13442814 |
| P50 | author | Nina C Zitzer | Q63634543 |
| P2093 | author name string | Min Wang | |
| Hong Lin | |||
| Robert A Baiocchi | |||
| Kris Vaddi | |||
| Ramiro Garzon | |||
| Parvathi Ranganathan | |||
| Jane E Jackman | |||
| Charuta Kale | |||
| Hannah K Choe | |||
| Yandi Gao | |||
| Maciej Pietrzak | |||
| Gregory K Behbehani | |||
| Yang W Zhang | |||
| Maria G Abad | |||
| Katiri Snyder | |||
| Anora Ignaci | |||
| Lotus Neidemire-Colley | |||
| Natalie E Sell | |||
| Raymond D Devine | |||
| P2860 | cites work | LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity | Q90402870 |
| Arginine methylation controls growth regulation by E2F-1 | Q24305116 | ||
| The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins | Q24548244 | ||
| Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes | Q24563451 | ||
| Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum | Q24594356 | ||
| A scaling normalization method for differential expression analysis of RNA-seq data | Q24628783 | ||
| Epigenetic regulators and their impact on therapy in acute myeloid leukemia | Q26765402 | ||
| The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity | Q27931859 | ||
| The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond | Q28085672 | ||
| Arginine methylation regulates the p53 response | Q28116284 | ||
| Mechanisms of type-I- and type-II-interferon-mediated signalling | Q28247893 | ||
| The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition | Q28301955 | ||
| Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF | Q28567709 | ||
| Protein arginine methylation in mammals: who, what, and why | Q29617309 | ||
| IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. | Q33853636 | ||
| In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. | Q33997187 | ||
| HISAT: a fast spliced aligner with low memory requirements | Q34043398 | ||
| Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD | Q34209366 | ||
| featureCounts: an efficient general purpose program for assigning sequence reads to genomic features | Q34384848 | ||
| Interferon-stimulated genes: a complex web of host defenses | Q34405609 | ||
| PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.). | Q35009896 | ||
| HDAC inhibition and graft versus host disease | Q35016985 | ||
| Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans | Q35029450 | ||
| T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function | Q35041966 | ||
| Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation | Q35450551 | ||
| Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice | Q35572384 | ||
| IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity | Q35733767 | ||
| Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation | Q36044823 | ||
| Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome | Q36055095 | ||
| Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis | Q36105914 | ||
| Role of Interferon-gamma in GVHD and GVL. | Q36347938 | ||
| IFNγR signaling mediates alloreactive T-cell trafficking and GVHD | Q36395621 | ||
| CD28 costimulatory signal induces protein arginine methylation in T cells. | Q36403312 | ||
| T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. | Q36706319 | ||
| Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease | Q36843812 | ||
| MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner | Q36907824 | ||
| Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells | Q36915913 | ||
| IL-17 contributes to CD4-mediated graft-versus-host disease | Q37071147 | ||
| In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations | Q37086953 | ||
| Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect | Q37095317 | ||
| PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. | Q37103890 | ||
| Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma | Q37188161 | ||
| Regulatory T-Cell Therapy for Graft-versus-host Disease | Q37309438 | ||
| PRMT5 is required for cell-cycle progression and p53 tumor suppressor function | Q37318470 | ||
| Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. | Q37368735 | ||
| Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease | Q37373067 | ||
| Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases | Q37414046 | ||
| PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. | Q37432768 | ||
| Dichotomous role of interferon-gamma in allogeneic bone marrow transplant | Q37435506 | ||
| STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity | Q37496786 | ||
| Causal analysis approaches in Ingenuity Pathway Analysis | Q37592031 | ||
| PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis | Q37625481 | ||
| Protein arginine methylation: a new handle on T lymphocytes? | Q37697984 | ||
| Protein arginine methyltransferases and cancer | Q38067063 | ||
| Epigenetic therapy in allogeneic hematopoietic stem cell transplantation | Q38112417 | ||
| Next generation treatment of acute graft-versus-host disease | Q38221028 | ||
| Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia | Q38667498 | ||
| Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo | Q38741352 | ||
| Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | Q38816505 | ||
| RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury | Q38829671 | ||
| Protein arginine methylation/demethylation and cancer | Q38935888 | ||
| Arginine Methylation: The Coming of Age. | Q39070637 | ||
| Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling | Q39618479 | ||
| The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation | Q40356364 | ||
| The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects | Q40555486 | ||
| Arginine methylation regulates IL-2 gene expression: a role for protein arginine methyltransferase 5 (PRMT5). | Q41927743 | ||
| The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling | Q42834494 | ||
| Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy | Q43164286 | ||
| Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis | Q44477645 | ||
| p53 methylation--the Arg-ument is clear | Q46120152 | ||
| Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma | Q47381020 | ||
| Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy | Q49679320 | ||
| PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma | Q50019708 | ||
| Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells | Q50034338 | ||
| New Insights into Graft-Versus-Host Disease and Graft Rejection | Q50425146 | ||
| Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Q50798708 | ||
| The expression of Th17-associated cytokines in human acute graft-versus-host disease. | Q50885897 | ||
| MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. | Q52714530 | ||
| Adoptively transferred donor IL-17-producing CD4+ T cells augment, but IL-17 alleviates, acute graft-versus-host disease. | Q52880882 | ||
| Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. | Q52932701 | ||
| Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses | Q57019922 | ||
| Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10 | Q57194209 | ||
| The interferon-dependent orchestration of innate and adaptive immunity after transplantation | Q57252623 | ||
| Type I-IFNs control GVHD and GVL responses after transplantation | Q57252624 | ||
| IFN differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract | Q57252630 | ||
| In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease | Q57384554 | ||
| Arginine methylation controls the strength of γc-family cytokine signaling in T cell maintenance | Q57464781 | ||
| In vitro Th17-polarized human CD4 T cells exacerbate xenogeneic graft-versus-host disease | Q57468066 | ||
| Effect of storage time and temperature on cell cycle analysis by mass cytometry | Q58087553 | ||
| Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) | Q64008518 | ||
| An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin | Q71881409 | ||
| Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning | Q73324704 | ||
| Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines | Q73894705 | ||
| Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells | Q74098005 | ||
| Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation | Q77293917 | ||
| IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation | Q83300076 | ||
| Graft-versus-host disease | Q83468020 | ||
| Background to hematopoietic cell transplantation, including post transplant immune recovery | Q84794952 | ||
| P577 | publication date | 2020-03-19 | |
| P1433 | published in | JCI insight | Q27727187 |
| P1476 | title | PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease |
Search more.